Last reviewed · How we verify

Aflibercept and ranibizumab

Instituto de Olhos de Goiania · FDA-approved active Small molecule

Aflibercept and ranibizumab is a Anti-VEGF agent Small molecule drug developed by Instituto de Olhos de Goiania. It is currently FDA-approved for Age-related macular degeneration (wet/neovascular), Diabetic macular edema, Retinal vein occlusion.

Aflibercept and ranibizumab are anti-VEGF agents that inhibit vascular endothelial growth factor to reduce abnormal blood vessel growth and leakage in the eye.

Aflibercept and ranibizumab are anti-VEGF agents that inhibit vascular endothelial growth factor to reduce abnormal blood vessel growth and leakage in the eye. Used for Age-related macular degeneration (wet/neovascular), Diabetic macular edema, Retinal vein occlusion.

At a glance

Generic nameAflibercept and ranibizumab
SponsorInstituto de Olhos de Goiania
Drug classAnti-VEGF agent
TargetVEGF-A (and VEGF-B for aflibercept)
ModalitySmall molecule
Therapeutic areaOphthalmology
PhaseFDA-approved

Mechanism of action

Aflibercept is a recombinant fusion protein that acts as a VEGF trap, binding and sequestering VEGF-A and VEGF-B. Ranibizumab is a monoclonal antibody fragment that directly binds and neutralizes VEGF-A. Both agents prevent VEGF-mediated angiogenesis and vascular permeability, reducing pathological neovascularization and edema in retinal diseases.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Aflibercept and ranibizumab

What is Aflibercept and ranibizumab?

Aflibercept and ranibizumab is a Anti-VEGF agent drug developed by Instituto de Olhos de Goiania, indicated for Age-related macular degeneration (wet/neovascular), Diabetic macular edema, Retinal vein occlusion.

How does Aflibercept and ranibizumab work?

Aflibercept and ranibizumab are anti-VEGF agents that inhibit vascular endothelial growth factor to reduce abnormal blood vessel growth and leakage in the eye.

What is Aflibercept and ranibizumab used for?

Aflibercept and ranibizumab is indicated for Age-related macular degeneration (wet/neovascular), Diabetic macular edema, Retinal vein occlusion, Diabetic retinopathy.

Who makes Aflibercept and ranibizumab?

Aflibercept and ranibizumab is developed and marketed by Instituto de Olhos de Goiania (see full Instituto de Olhos de Goiania pipeline at /company/instituto-de-olhos-de-goiania).

What drug class is Aflibercept and ranibizumab in?

Aflibercept and ranibizumab belongs to the Anti-VEGF agent class. See all Anti-VEGF agent drugs at /class/anti-vegf-agent.

What development phase is Aflibercept and ranibizumab in?

Aflibercept and ranibizumab is FDA-approved (marketed).

What are the side effects of Aflibercept and ranibizumab?

Common side effects of Aflibercept and ranibizumab include Conjunctival hemorrhage, Eye pain, Floaters, Intraocular pressure elevation, Endophthalmitis, Retinal detachment.

What does Aflibercept and ranibizumab target?

Aflibercept and ranibizumab targets VEGF-A (and VEGF-B for aflibercept) and is a Anti-VEGF agent.

Related